PMC:4100259 / 1347-3909
Annnotations
NEUROSES
{"project":"NEUROSES","denotations":[{"id":"T35","span":{"begin":234,"end":242},"obj":"CHEBI_23888"},{"id":"T36","span":{"begin":430,"end":435},"obj":"CHEBI_23888"},{"id":"T37","span":{"begin":670,"end":675},"obj":"CHEBI_23888"},{"id":"T38","span":{"begin":2011,"end":2016},"obj":"CHEBI_23888"},{"id":"T39","span":{"begin":480,"end":490},"obj":"CHEBI_4056"},{"id":"T40","span":{"begin":872,"end":875},"obj":"CHEBI_38559"},{"id":"T41","span":{"begin":921,"end":931},"obj":"CHEBI_35610"},{"id":"T42","span":{"begin":1269,"end":1279},"obj":"CHEBI_35610"},{"id":"T43","span":{"begin":948,"end":957},"obj":"CHEBI_41774"},{"id":"T44","span":{"begin":979,"end":986},"obj":"PATO_0001997"},{"id":"T45","span":{"begin":1094,"end":1101},"obj":"PATO_0001997"},{"id":"T46","span":{"begin":1014,"end":1024},"obj":"CHEBI_35222"},{"id":"T47","span":{"begin":1058,"end":1064},"obj":"PATO_0002354"},{"id":"T48","span":{"begin":1065,"end":1076},"obj":"CHEBI_25212"},{"id":"T49","span":{"begin":1123,"end":1139},"obj":"CHEBI_4027"},{"id":"T50","span":{"begin":1123,"end":1139},"obj":"CHEBI_4026"},{"id":"T51","span":{"begin":1193,"end":1202},"obj":"PATO_0000470"},{"id":"T52","span":{"begin":1370,"end":1380},"obj":"CHEBI_75988"},{"id":"T53","span":{"begin":1382,"end":1394},"obj":"CHEBI_27656"},{"id":"T54","span":{"begin":1428,"end":1436},"obj":"CHEBI_45783"},{"id":"T55","span":{"begin":1451,"end":1461},"obj":"CHEBI_45863"},{"id":"T56","span":{"begin":1466,"end":1475},"obj":"CHEBI_4672"},{"id":"T57","span":{"begin":1466,"end":1475},"obj":"CHEBI_59809"},{"id":"T58","span":{"begin":1502,"end":1513},"obj":"CHEBI_28445"},{"id":"T59","span":{"begin":1591,"end":1601},"obj":"CHEBI_5864"},{"id":"T60","span":{"begin":1621,"end":1632},"obj":"CHEBI_33281"},{"id":"T61","span":{"begin":1621,"end":1632},"obj":"CHEBI_22582"},{"id":"T62","span":{"begin":2224,"end":2228},"obj":"PATO_0000469"}],"text":"1. Introduction\nValerian “can interfere in an unwanted way with the oncological cancer therapy” or valerian “can diminish the efficacy of cancer therapeutics.” Statements like these can be found in published features on complementary medicine for cancer patients (Sloan Kettering Center 2012 [1]). In a very popular book on integrative oncology published by Sparreboom and Baker [2], it is stated that it is known for some herbal drugs that they can influence the activity of the cytochrome system and thereby may change the effect of chemotherapy. It is further stated that cancer patients often have difficulties to sleep and are restless, so that they can use herbal drugs such as valerian in order to avoid chemically defined sedatives and hypnotics as they fear becoming addicted. However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.\nThis would reduce the effect of several cytostatic substances. For tamoxifen, the plasma level is reduced by CYP3A4 inductors, while inhibitors of CYP2D6 can lower the level of active metabolites, both leading to reduced efficacy. In case of cyclophosphamide, metabolic activation by CYP2D6 is necessary that is increased by inductors of this isoenzyme. The plasma level of several other cytostatic substances is lowered by CYP3A4 inductors. Examples are the epipodophyllotoxin derivative teniposide, camptothecin, tyrosine kinase inhibitors like imatinib, taxanes like paclitaxel and docetaxel, and vinca alkaloids like vincristine. CYP3A4 inductors also may reduce the activity of alkylating substances like ifosfamide and some antitumor antibiotics [2].\nIn several websites directed to patients (http://www.cancer.org, http://www.mskcc.org), the use of valerian in cancer is also questioned due to its interaction potential. By the way, Scientific American elected the latter website just a year after foundation as one of the best five US medicinal websites.\nMore than 70% of all cancer patients are very interested in herbal drugs. However, many of them do not inform their oncologist about their use [3, 4]. As 19 to 75% of all cancer patients suffer from sleep disturbances [5], warnings against the use of valerian preparations have a high impact on these patients. However, it has to be ascertained that warnings that valerian may cause interactions with other medicines are backed by valid evidence supporting such an assumption and that they are therefore scientifically correct. Therefore, we conducted a review in order to assess the interaction potential of valerian."}
2_test
{"project":"2_test","denotations":[{"id":"25093031-23813259-29486299","span":{"begin":2091,"end":2092},"obj":"23813259"},{"id":"25093031-15165499-29486300","span":{"begin":2163,"end":2164},"obj":"15165499"}],"text":"1. Introduction\nValerian “can interfere in an unwanted way with the oncological cancer therapy” or valerian “can diminish the efficacy of cancer therapeutics.” Statements like these can be found in published features on complementary medicine for cancer patients (Sloan Kettering Center 2012 [1]). In a very popular book on integrative oncology published by Sparreboom and Baker [2], it is stated that it is known for some herbal drugs that they can influence the activity of the cytochrome system and thereby may change the effect of chemotherapy. It is further stated that cancer patients often have difficulties to sleep and are restless, so that they can use herbal drugs such as valerian in order to avoid chemically defined sedatives and hypnotics as they fear becoming addicted. However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.\nThis would reduce the effect of several cytostatic substances. For tamoxifen, the plasma level is reduced by CYP3A4 inductors, while inhibitors of CYP2D6 can lower the level of active metabolites, both leading to reduced efficacy. In case of cyclophosphamide, metabolic activation by CYP2D6 is necessary that is increased by inductors of this isoenzyme. The plasma level of several other cytostatic substances is lowered by CYP3A4 inductors. Examples are the epipodophyllotoxin derivative teniposide, camptothecin, tyrosine kinase inhibitors like imatinib, taxanes like paclitaxel and docetaxel, and vinca alkaloids like vincristine. CYP3A4 inductors also may reduce the activity of alkylating substances like ifosfamide and some antitumor antibiotics [2].\nIn several websites directed to patients (http://www.cancer.org, http://www.mskcc.org), the use of valerian in cancer is also questioned due to its interaction potential. By the way, Scientific American elected the latter website just a year after foundation as one of the best five US medicinal websites.\nMore than 70% of all cancer patients are very interested in herbal drugs. However, many of them do not inform their oncologist about their use [3, 4]. As 19 to 75% of all cancer patients suffer from sleep disturbances [5], warnings against the use of valerian preparations have a high impact on these patients. However, it has to be ascertained that warnings that valerian may cause interactions with other medicines are backed by valid evidence supporting such an assumption and that they are therefore scientifically correct. Therefore, we conducted a review in order to assess the interaction potential of valerian."}
MyTest
{"project":"MyTest","denotations":[{"id":"25093031-23813259-29486299","span":{"begin":2091,"end":2092},"obj":"23813259"},{"id":"25093031-15165499-29486300","span":{"begin":2163,"end":2164},"obj":"15165499"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"1. Introduction\nValerian “can interfere in an unwanted way with the oncological cancer therapy” or valerian “can diminish the efficacy of cancer therapeutics.” Statements like these can be found in published features on complementary medicine for cancer patients (Sloan Kettering Center 2012 [1]). In a very popular book on integrative oncology published by Sparreboom and Baker [2], it is stated that it is known for some herbal drugs that they can influence the activity of the cytochrome system and thereby may change the effect of chemotherapy. It is further stated that cancer patients often have difficulties to sleep and are restless, so that they can use herbal drugs such as valerian in order to avoid chemically defined sedatives and hypnotics as they fear becoming addicted. However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.\nThis would reduce the effect of several cytostatic substances. For tamoxifen, the plasma level is reduced by CYP3A4 inductors, while inhibitors of CYP2D6 can lower the level of active metabolites, both leading to reduced efficacy. In case of cyclophosphamide, metabolic activation by CYP2D6 is necessary that is increased by inductors of this isoenzyme. The plasma level of several other cytostatic substances is lowered by CYP3A4 inductors. Examples are the epipodophyllotoxin derivative teniposide, camptothecin, tyrosine kinase inhibitors like imatinib, taxanes like paclitaxel and docetaxel, and vinca alkaloids like vincristine. CYP3A4 inductors also may reduce the activity of alkylating substances like ifosfamide and some antitumor antibiotics [2].\nIn several websites directed to patients (http://www.cancer.org, http://www.mskcc.org), the use of valerian in cancer is also questioned due to its interaction potential. By the way, Scientific American elected the latter website just a year after foundation as one of the best five US medicinal websites.\nMore than 70% of all cancer patients are very interested in herbal drugs. However, many of them do not inform their oncologist about their use [3, 4]. As 19 to 75% of all cancer patients suffer from sleep disturbances [5], warnings against the use of valerian preparations have a high impact on these patients. However, it has to be ascertained that warnings that valerian may cause interactions with other medicines are backed by valid evidence supporting such an assumption and that they are therefore scientifically correct. Therefore, we conducted a review in order to assess the interaction potential of valerian."}